TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE)-- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical program ...
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the Institutional Review Board (“IRB”) at ...
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies ...
Peer-reviewed randomized controlled study by People Science and Mimio Health, published in Nature Scientific Reports LOS ANGELES, March 2, 2026 /PRNewswire/ -- People Science today announced the ...
Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo. Based on the encouraging weight loss, as well as the safety and tolerability results ...
Long-Term Prospective Cohort Study of Cervical Cancer Screening Using Triage of Women Who Are Human Papillomavirus–Positive With Dual Stain and Human Papillomavirus Genotyping Participants enrolled ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC, the “Company”), the biopharmaceutical company focused on the treatment of diabetes and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results